Trials / Unknown
UnknownNCT03469063
Impact of AferBio® on Quality of Life and Chemotherapy Toxicity in Lung Cancer Patients
Randomized Clinical Trial to Assess the Impact of AferBio® on Quality of Life and Toxicity to Chemotherapy in Patients With NSCLC Beginning Second-line Palliative Mono-chemotherapy
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 104 (estimated)
- Sponsor
- Barretos Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The AFERBIO study will evaluates safety and potential benefit of AferBio® in patients with non-small cell lung cancer undergoing at least a second-line palliative monochemotherapy. AferBio® is a fermented supplement in powder form obtained through biotechnological processes developed in Brazil. In this double-blind placebo-controlled randomized clinical trial, participants starting a new palliative regimen will be allocated to AferBio® or placebo. The primary aim will be to compare health-related QOL scores among the arms of the study over time.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | AferBio | Patients will use the product (AferBio/Placebo) once a day for seven days, and then twice a day, continuously (for a total of three months of use). |
Timeline
- Start date
- 2018-06-28
- Primary completion
- 2020-02-28
- Completion
- 2020-06-30
- First posted
- 2018-03-19
- Last updated
- 2018-06-14
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT03469063. Inclusion in this directory is not an endorsement.